omeprazole has been researched along with Benign Neoplasms in 15 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 9.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 5.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| " After cocktail alone or in combination with adavosertib administration, 24-h pharmacokinetic sampling occurred for probe substrates and their respective metabolites paraxanthine, 5-hydroxyomeprazole (5-HO), and 1'-hydroxymidazolam (1'-HM)." | 3.30 | Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. ( Ah-See, ML; Edenfield, WJ; Lewis, LD; Li, Y; Mugundu, GM; Nadeau, L; Någård, M; Ottesen, LH; Safran, HP; Strauss, J; Wise-Draper, T, 2023) |
| "Omeprazole was not helpful in reducing the frequency or severity of GI AEs and was associated with more frequent and severer GI AEs in dogs with cancer treated with single agent piroxicam." | 3.01 | A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine. ( Fulkerson, CM; Moore, GE; Shaevitz, MH, 2021) |
| "Fedratinib is a weak inhibitor of CYP2D6, and a moderate inhibitor of CYP2C19 and CYP3A4." | 2.94 | Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. ( Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J, 2020) |
| "This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein." | 2.87 | Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. ( Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H, 2018) |
| " Neither were there significant differences in the absolute nadir and percentage decrease of WBC and ANC, nor on the incidence and severity of neutropenia, febrile neutropenia, diarrhoea, nausea and vomiting when irinotecan was combined with omeprazole." | 2.76 | Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. ( de Bruijn, P; de Jong, FA; Konings, IR; Lam, MH; Loos, WJ; Mathijssen, RH; van der Bol, JM; van Meerten, E; Verweij, J; Wiemer, EA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mine, K | 1 |
| Kawashiri, T | 1 |
| Inoue, M | 1 |
| Kobayashi, D | 1 |
| Mori, K | 1 |
| Hiromoto, S | 1 |
| Kudamatsu, H | 1 |
| Uchida, M | 1 |
| Egashira, N | 1 |
| Koyanagi, S | 1 |
| Ohdo, S | 1 |
| Shimazoe, T | 1 |
| Någård, M | 1 |
| Ah-See, ML | 1 |
| Strauss, J | 1 |
| Wise-Draper, T | 1 |
| Safran, HP | 1 |
| Nadeau, L | 1 |
| Edenfield, WJ | 1 |
| Lewis, LD | 1 |
| Ottesen, LH | 1 |
| Li, Y | 1 |
| Mugundu, GM | 1 |
| Paz, MFCJ | 1 |
| de Alencar, MVOB | 1 |
| de Lima, RMP | 1 |
| Sobral, ALP | 1 |
| do Nascimento, GTM | 1 |
| Dos Reis, CA | 1 |
| Coêlho, MDPSS | 1 |
| do Nascimento, MLLB | 1 |
| Gomes Júnior, AL | 1 |
| Machado, KDC | 1 |
| de Menezes, APM | 1 |
| de Lima, RMT | 1 |
| de Oliveira Filho, JWG | 1 |
| Dias, ACS | 1 |
| Dos Reis, AC | 1 |
| da Mata, AMOF | 1 |
| Machado, SA | 1 |
| Sousa, CDC | 1 |
| da Silva, FCC | 1 |
| Islam, MT | 1 |
| de Castro E Sousa, JM | 1 |
| Melo Cavalcante, AAC | 1 |
| Ogasawara, K | 1 |
| LoRusso, PM | 1 |
| Olszanski, AJ | 1 |
| Rixe, O | 1 |
| Xu, C | 1 |
| Yin, J | 1 |
| Palmisano, M | 1 |
| Krishna, G | 1 |
| Shaevitz, MH | 1 |
| Moore, GE | 1 |
| Fulkerson, CM | 1 |
| Tachibana, M | 1 |
| Papadopoulos, KP | 1 |
| Strickler, JH | 1 |
| Puzanov, I | 1 |
| Gajee, R | 1 |
| Wang, Y | 1 |
| Zahir, H | 1 |
| Helsby, NA | 1 |
| Lo, WY | 1 |
| Sharples, K | 1 |
| Riley, G | 1 |
| Murray, M | 1 |
| Spells, K | 1 |
| Dzhelai, M | 1 |
| Simpson, A | 1 |
| Findlay, M | 1 |
| Quinn, DI | 1 |
| Nemunaitis, J | 1 |
| Fuloria, J | 1 |
| Britten, CD | 1 |
| Gabrail, N | 1 |
| Yee, L | 1 |
| Acharya, M | 1 |
| Chan, K | 1 |
| Cohen, N | 1 |
| Dudov, A | 1 |
| van der Bol, JM | 1 |
| Loos, WJ | 1 |
| de Jong, FA | 1 |
| van Meerten, E | 1 |
| Konings, IR | 1 |
| Lam, MH | 1 |
| de Bruijn, P | 1 |
| Wiemer, EA | 1 |
| Verweij, J | 1 |
| Mathijssen, RH | 1 |
| Tsimberidou, AM | 1 |
| Lewis, N | 1 |
| Reid, T | 1 |
| Burris, H | 1 |
| Urban, P | 1 |
| Tan, EY | 1 |
| Anand, S | 1 |
| Uehara, C | 1 |
| Kurzrock, R | 1 |
| Reimer, C | 1 |
| Bytzer, P | 1 |
| Ma, Q | 1 |
| Lu, AY | 1 |
| Williams, ML | 1 |
| Bhargava, P | 1 |
| Cherrouk, I | 1 |
| Marshall, JL | 1 |
| Flockhart, DA | 1 |
| Wainer, IW | 1 |
| Sheptulin, AA | 1 |
| Lucier, GW | 1 |
| Thompson, CL | 1 |
| Hoel, DG | 1 |
3 reviews available for omeprazole and Benign Neoplasms
| Article | Year |
|---|---|
Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer.
Topics: Animals; Genomic Instability; Humans; Neoplasms; Omeprazole; Proton Pump Inhibitors; Rats | 2020 |
CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies.
Topics: Amines; Animals; Anti-Ulcer Agents; Benzo(a)pyrene; Biotransformation; Carcinogens; Cell Transformat | 2007 |
[Safety profile of pariet clinical use (a literature review)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; | 2001 |
7 trials available for omeprazole and Benign Neoplasms
| Article | Year |
|---|---|
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochr | 2023 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross | 2020 |
A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine.
Topics: Animals; Dog Diseases; Dogs; Famotidine; Incidence; Neoplasms; Omeprazole; Piroxicam; Prospective St | 2021 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B | 2018 |
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bor | 2009 |
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; | 2011 |
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2011 |
5 other studies available for omeprazole and Benign Neoplasms
| Article | Year |
|---|---|
Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database.
Topics: Animals; Antineoplastic Agents; Mice; Neoplasms; Omeprazole; Oxaliplatin; Peripheral Nervous System | 2022 |
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.
Topics: Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gen | 2008 |
[Adverse events associated with long-term use of proton pump inhibitors].
Topics: Anti-Ulcer Agents; Bacterial Infections; Congenital Abnormalities; Dyspepsia; Fractures, Bone; Gastr | 2012 |
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 En | 2000 |
Omeprazole, cytochrome P450, and chemical carcinogenesis.
Topics: Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Neoplasms; Omeprazole; Receptors, Aryl Hyd | 1992 |